Sun Pharmaceutical Industries Ltd.’s senior management fielded a number of questions around strategic issues at its earnings call for the fiscal first quarter, including whether the firm plans more definitive steps in the biosimilars segment and its alliance in China.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?